Study identifier:MB102-066
ClinicalTrials.gov identifier:NCT01165268
EudraCT identifier:N/A
CTIS identifier:N/A
Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects with Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Phase 1
Yes
Dapagliflozin
All
24
Interventional
18 Years - 65 Years
Allocation: Non-randomized
Endpoint Classification: Pharmacokinetics/dynamics
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verified 01 Nov 2016 by AstraZeneca
AstraZeneca
Bristol-Myers Squibb
No locations available
Arms | Assigned Interventions |
---|---|
Active Comparator: Dapagliflozin (T2DM) | Drug: Dapagliflozin Tablets, Oral, 10 mg, Once daily, 7 days |
Active Comparator: Dapagliflozin (Healthy Subjects) | Drug: Dapagliflozin Tablets, Oral, 10 mg, Once daily, 7 days |